These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 7291202

  • 21. Homozygous G6PD deficiency and propacetamol induced hemolysis.
    Oliver M, Coton T, Badens C, Dehan C, Lena-Russo D, Moalic JL.
    Haematologica; 2001 Sep; 86(9):987-8. PubMed ID: 11532629
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Alterations in normal and G-6-PD deficient human erythrocytes of various ages after exposure to metabolites of hemolytic drugs.
    Fraser IM, Tilton BE, Vesell ES.
    Pharmacology; 1971 Sep; 5(3):173-87. PubMed ID: 5119006
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Dapsone-induced hemolytic anemia: effect of dapsone hydroxylamine on sulfhydryl status, membrane skeletal proteins and morphology of human and rat erythrocytes.
    McMillan DC, Simson JV, Budinsky RA, Jollow DJ.
    J Pharmacol Exp Ther; 1995 Jul; 274(1):540-7. PubMed ID: 7616443
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Dynamic simulation of red blood cell metabolism and its application to the analysis of a pathological condition.
    Nakayama Y, Kinoshita A, Tomita M.
    Theor Biol Med Model; 2005 May 09; 2():18. PubMed ID: 15882454
    [Abstract] [Full Text] [Related]

  • 33. Feprazone: absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects.
    Meloni T, Forteleoni G, Serra M, Daniotti S, Negri L, Giuntini P, Canepa L, Gaetani GF.
    J Clin Pharmacol; 1982 May 09; 22(8-9):418-20. PubMed ID: 7130431
    [Abstract] [Full Text] [Related]

  • 34. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.
    Bluhm RE, Adedoyin A, McCarver DG, Branch RA.
    Clin Pharmacol Ther; 1999 Jun 09; 65(6):598-605. PubMed ID: 10391665
    [Abstract] [Full Text] [Related]

  • 35. The two PM(2.5) (fine) and PM(2.5-10) (coarse) fractions: evidence of different biological activity.
    Diociaiuti M, Balduzzi M, De Berardis B, Cattani G, Stacchini G, Ziemacki G, Marconi A, Paoletti L.
    Environ Res; 2001 Jul 09; 86(3):254-62. PubMed ID: 11453676
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinical pharmacology of diformyldapsone.
    Cucinell SA, Rebert C, Clyde D.
    J Clin Pharmacol; 1974 Jan 09; 14(1):51-7. PubMed ID: 4491908
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Oxidative stress, glucose-6-phosphate dehydrogenase and the red cell.
    Jollow DJ, McMillan DC.
    Adv Exp Med Biol; 2001 Jan 09; 500():595-605. PubMed ID: 11765001
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.